Global Idiopathic Pulmonary Fibrosis 2016-2020 - Market to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Global Idiopathic Pulmonary Fibrosis 2016-2020 - Market to grow at a CAGR of 23.97%

Dublin, May 23, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Idiopathic Pulmonary Fibrosis 2016-2020" report to their offering. The analysts forecast the global idiopathic pulmonary fibrosis market to grow at a CAGR of 23.97% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global idiopathic pulmonary fibrosis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of idiopathic pulmonary fibrosis. The report also includes a discussion of the key vendors operating in this market.

Idiopathic pulmonary fibrosis belongs to a group of lung diseases known as interstitial lung diseases. It affects people in the age group 50-70 years. Diagnosis is effected by the exclusion of other interstitial lung diseases. High-resolution computed tomography (CT) is often employed to confirm the presence of the disease. There is no permanent cure for this disease; therefore, treatment involves relieving underlying symptoms. Nintedanib and pirfenidone are the two approved drugs for the treatment of idiopathic pulmonary fibrosis. Corticosteroids and immunosuppressive drugs are also used for the treatment. An emerging market trend is the rise in patient assistance programs. Vendors in the market provide co-pay assistance to people who purchase the indicated medications for idiopathic pulmonary fibrosis. For instance, Roche has a co-pay assistance program to provide financial assistance to patients who purchase Esbriet. According to the Esbriet Co-pay Card Program, an eligible patient receives a 12-month prescription free of cost, attaining a maximum benefit of $24,000 during this period. The company also provides Esbriet Access Solutions that provide co-pay cards, assistance in getting drugs, and provide healthcare coverage to patients. According to the report, a possible growth driver is the unmet medical needs of many patients. Due to the unknown disease etiology, there is no specific cure for idiopathic pulmonary fibrosis. Therapies that target the exact cause of the disease cannot be developed owing to the idiopathic nature of the disease. Even the drugs marketed for the symptomatic treatment of the disease present different effects such as upper respiratory tract infections, liver problems, nausea and vomiting, diarrhea, headache, heartburn, weight loss, and high blood pressure. This results in decreased patient compliance, creating an unmet need in the market. Pharmaceutical companies and researchers are interested in developing a drug that provides a complete cure for the disease, with minimal side effects. Further, the report states that one challenge that could market growth is the lack of proper diagnosis of this condition. Key vendors

- Baxter International - Boehringer Ingelheim - F.Hoffmann-La Roche - Prometheus Laboratories Other prominent vendors

- Afferent Pharmaceuticals - Amgen - Biogen - Bristol-Myers Squibb - Cipla - FibroGen - Gilead Sciences - GlaxoSmithKline - GNI Group - Horizon Pharma - ImmuneWorks - MediciNova - MedImmune (subsidiary of AstraZeneca) - Novartis - Pfizer - Promedior - ProMetic Life Sciences - Sanofi - Shionogi - Zai Lab

Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Disease overview - Understanding the disease - Pathogenesis - Signs and symptoms - Diagnosis - Management - Epidemiology PART 06: Pipeline analysis - Lebrikizumab - Tipelukast - Tralokinumab - FG-3019 - Simtuzumab - BMS-986020 - AF-219 - SAR156597 - BG00011 - PRM-151 - PBI-4050 PART 07: Market landscape - Market overview - Market size and forecast - Five forces analysis PART 08: Market segmentation by ROA - Oral - Parenteral PART 09: Market segmentation by drug class - Systemic corticosteroids - Immunosuppressants - Tyrosine kinase inhibitors - Anti-fibrotic agents PART 10: Geographical segmentation - Global idiopathic pulmonary fibrosis market by geographical segmentation 2015-2020 - Idiopathic pulmonary fibrosis market in Americas - Idiopathic pulmonary fibrosis market in EMEA - Idiopathic pulmonary fibrosis market in APAC PART 11: Market drivers - Special regulatory designations for pipeline candidates - Growth in patient population - Unmet medical needs PART 12: Impact of drivers PART 13: Market challenges - Unknown disease etiology - Lack of proper diagnosis - Increased use of off-label and alternative therapies PART 14: Impact of drivers and challenges PART 15: Market trends - Patient assistance programs - Increase in M&A - Rise in public awareness PART 16: Vendor landscape - Competitive scenario - Market share analysis 2015 - Baxter International - Boehringer Ingelheim - F Hoffmann-La Roche - Prometheus Laboratories - Other prominent vendors PART 17: Appendix For more information visit http://www.researchandmarkets.com/research/6f...idiopathic

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Healthcare and Medical Devices

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Century Lithium Clears a Crucial Nevada Permit Gate

Updated Category News Views 65

Permitting news rarely rings a cash register, but it can stop one from being bolted shut. Century Lithium has received confirmation from the Bureau of Land Management’s Tonopah Field Office that baseline studies for its wholly owned Angel Island lithium project in Esmeralda County, Nevada, are complete. The agency also set the project on the Environmental Impact...

Continue Reading
Global-E Faces Fresh Scrutiny After Muted Quarterly Outlook

Updated Category News Views 28

A guidance bump that barely clears the curb can still wreck a stock. That is the unpleasant read-through from Global-E Online's third-quarter 2026 report: revenue guidance went higher, but not high enough to persuade investors that the business was pulling away from expectations. Shares fell after the release, and a securities-law investigation announced November 19 has...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 182

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Blue Moon Closes Turner Deal, Eyes Nevada Mill Plan

Updated Category News Views 52

A shuttered Oregon copper-gold deposit just became part of Blue Moon’s puzzle, and the real question is whether the pieces can ever be made to fit cheaply enough to matter. Turner Adds a Nearby VMS Angle Blue Moon Metals has completed its acquisition of the Turner copper-gold deposit in O’Brien, Oregon, from Gold Coast Mining. The formal closing follows the September...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
DoorDash Grocery Tools Need a Hard Look Before Checkout

Updated Category News Views 107

A grocery cart built in thirty seconds can still nick your wallet all week. That is the part buried beneath the convenience pitch around DoorDash's grocery tools: planning is useful, but convenience only earns its keep when the final basket, delivery charge, substitutions, and timing actually line up. The 2026 review from Expert Consumers highlights features that are...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 96

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 116

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 92

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Vail Resorts Bets on Music to Deepen Epic Pass Demand

Updated Category News Views 119

A bass drop at 11,000 feet is not merely a party trick when you run 42 mountain resorts. Vail Resorts is putting live music, après programming and destination events squarely beside skiing and riding for winter 2026-27, and the business logic is pretty plain: give people another reason to buy early, stay longer and return with friends. For investors watching MTN, this is...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating Autohome Inc.'s Financial Results for 2025

Updated Category News Views 150

Autohome Inc.'s Upcoming Financial Results Announcement Autohome Inc. (NYSE: ATHM) is on the verge of announcing its financial results for the second quarter and six months period ending June 30, 2025. As a leading platform for automobile consumers, Autohome continues to grow and adapt in an evolving market. Key Details on the Earnings Announcement The earnings report...

Continue Reading
NEXGEL Welcomes Industry Expert Kip Crecca to Advisory Team

Updated Category News Views 100

NEXGEL Expands Scientific Expertise with New Appointment NEXGEL, Inc. (NASDAQ: NXGL), renowned for its innovative medical and over-the-counter (OTC) products, has recently announced an exciting development. The company is thrilled to welcome Kip Crecca to its Scientific Advisory Board. This strategic addition showcases NEXGEL's dedication to enhancing its healthcare...

Continue Reading
Exciting Mixed-Use Development Takes Shape in Downtown Area

Updated Category News Views 318

Reimagining Urban Spaces: The Lewter District Development In an exciting development for urban living, RNGD and Emergent Properties are pioneering a remarkable mixed-use community known as the Lewter District. This project is set on a 1.5-acre plot, featuring 14 townhomes, a Class A office building, and an inviting farm-to-table restaurant, bar, and bakery. It's an...

Continue Reading
37th Parallel Expands DFW Footprint with Key Acquisition

Updated Category News Views 97

Picking Up Momentum in Dallas-Fort Worth Real Estate 37th Parallel Properties isn't messing around in the Dallas-Fort Worth market. They've snapped up Woodbridge Villas, a prime multifamily asset with 222 units tucked away in Sachse, Texas—a place with more charm than lawn gnomes in spring. This acquisition helps them expand their already hefty footprint in the South...

Continue Reading
Microchip Technology Announces Revenue Changes and Restructuring

Updated Category News Views 169

Microchip Technology's Updated Revenue Guidance for December Quarter Recently, Microchip Technology Incorporated, a prominent provider of smart embedded control solutions, has updated its revenue outlook for the upcoming quarter. The latest forecasts indicate a decline, with expectations set close to the lower end of their original guidance at $1.025 billion. This...

Continue Reading